Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Penumbra Continues Push Into Peripheral Therapies

Executive Summary

Penumbra Inc. continues its push into peripheral therapies with the recent US introduction of the POD Packing Coil, designed to occlude arteries and veins in conjunction with the company's Ruby and POD (Penumbra Occlusion Device) embolization products for the treatment of peripheral vascular conditions such as aneurysms and fistulas. The POD Packing coil, which earned a 510(k) in 2015 along with a neurovascular version of the device, grew out of the platinum coil technologies used to treat brain aneurysm.

You may also be interested in...



Not Too ATTRACTive Data For Catheter Thrombolysis In Combatting Post-Thrombotic Syndrome

Randomized trial results show pharmacomechanical, catheter-directed thrombolysis does not reduce the development of post-thrombotic syndrome in patients treated for deep-vein thrombosis. The study’s investigator suggests limiting the procedure to treatment of large iliofemoral blood clots causing major symptoms in patients who are at low risk of bleeding.

Personal Care Next Target For UK Competition Authority ‘Greenwashing’ Audit

Manufacturers of UK personal care products watch out, the Competition and Markets Authority is on the look-out for false, exaggerated and/or vague sustainability claims, and may be targeting bigger players to make an example for the rest of the sector. And consumer health might be next. HBW Insight returns to advice from marketing expert Jo Stephenson on how to avoid greenwashing, based on the CMA's own extensive Green Claims Code.

UK MHRA’s New And Increased Medtech Fees In Force in April

One outcome of last year’s public consultation on UK MHRA fees is a hefty uplift in charges payable by medtech manufacturers in 2023, beyond which the agency is keen to pursue a new fees and charges plan.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel